Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...

Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial ...

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

Typical nerve conduction abnormalities indicating demyelination are seen in (b): prolonged distal latencies, temporal dispersion, and amplitude reduction of action potentials. Note that the ...

The destruction of myelin sheaths—demyelination—can occur in the context of brain inflammation and can lead to cognitive, movement and other neurological problems. The phenomenon is seen in ...

New research findings dispel the dogma that slower hyponatremia correction is better. Faster correction of severe hyponatremia is associated with a lower death rate, investigators report.

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...